antalarmin

ant·a·lar·min

(ant-ă-larm'in),
Prototype small molecular weight corticotropin-releasing hormone or factor (CRH or CRF) antagonist that interacts with CRH type 1 receptors to inhibit behavioral and physical aspects of the stress response.
[ant- + alarm + in]
References in periodicals archive ?
Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rate.
Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout.
The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats.
Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF 1 receptor antagonist antalarmin and by CRF1 receptor knockout.
According to those who worked on the studies, the research community has begun to develop antalarmin for use in humans.
Essentially, antalarmin switches off the stress circuit, said Dr.
A host of animal studies shows that antalarmin selectively binds to CRH 1 receptors, thus blocking the binding of CRH.
Fewer embryos attached successfully to the uterus in rats receiving antalarmin than in control rats.
Antalarmin received on or after the ninth day of the rats' 3-week gestation period, however, didn't disrupt pregnancies.
The impact of the nonpeptide corticotrophin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress.
A host of animal studies show that antalarmin selectively binds to CRH 1 receptors, thus blocking the binding of CRH.
Antalarmin itself is not likely to reach the market because pharmacokinetic problems confound its utility as a human drug.